Category Archives: Corporate

Latest From Corporate

Welcome to Philadelphia and to BIO 2015!

Jim Greenwood

Over the course of the next few days, you will have the opportunity to hear from leaders from across our industry and to make the types of connections and partnerships that will take your business and your science to the next level. I am particularly looking forward to a wide ranging conversation with legendary journalist Tom Brokaw and a keynote session on digital health and the future of medical innovation with Dr. Eric Topol. We also Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

Jim Greenwood in New York Times: Specialty Tiers Limit Patient Access

Jim Greenwood

Today, the New York Times published a letter from Jim Greenwood, BIO’s President and CEO. Greenwood’s letter discusses the problems that expanded use of specialty tier cost-sharing by the insurance industry are posing for patients, limiting their access to lifesaving therapies and cures. Breakthrough treatments cost billions of dollars, and investors will only take on such risks if they can expect a reasonable return on their investment. The full text of the letter is below: To Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Jim Greenwood on the Road: Opening Bell at NASDAQ

Jim Ringing Nasdaq Bell

Jim Greenwood, BIO’s President and CEO, rang the opening bell this morning at the NASDAQ MarketSite in New York. Joining him on the stage were a number of BIO members and affiliates, including NewYorkBIO Executive Director Nathan Tinker, Pennsylvania Bio President Christopher Molineaux, DelawareBio Chairman Christopher Yochim, and BioNJ President Debbie Hart. Several BIO member companies were also represented, including Acorda Therapeutics President and CEO Ron Cohen, who also serves as Vice Chair of BIO’s Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Value of Innovation to Save and Transform Lives

lab_tech

Patients have greater hope for cures to today’s most complex and challenging diseases thanks to modern specialty medicines, which allow doctors and patients to focus on prevention and avoid hospital care altogether. With the potential to save countless lives and improve so many more, today’s innovative life-enhancing medicines and therapies provide economic value far beyond their cost. The debate surrounding the value of modern specialty medicines focuses narrowly on one aspect – cost – while Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

When The Deck is Stacked Against Innovators, Everyone Loses

US_Patent_And_Trademark_Office

Yesterday, I took part in a series of successful meetings on Capitol Hill regarding the USPTO’s Inter Partes Review system (IPR). Joined by several of BIO’s member companies, we expressed our concerns with how the system is evolving into one which makes it easier for IPR challengers to win than in Federal Court. The implementation of the IPR system – developed through the 2011 America Invests Act – has unintentionally invited abuses of the USPTO Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,